71 related articles for article (PubMed ID: 21883476)
1. Genetic variations in multiple myeloma II: association with effect of treatment.
Vangsted A; Klausen TW; Vogel U
Eur J Haematol; 2012 Feb; 88(2):93-117. PubMed ID: 21883476
[TBL] [Abstract][Full Text] [Related]
2. Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.
Vangsted AJ; Klausen TW; Abildgaard N; Andersen NF; Gimsing P; Gregersen H; Nexø BA; Vogel U
Ann Hematol; 2011 Oct; 90(10):1173-81. PubMed ID: 21347685
[TBL] [Abstract][Full Text] [Related]
3. Impact on response and survival of DNA repair single nucleotide polymorphisms in relapsed or refractory multiple myeloma patients treated with thalidomide.
Cibeira MT; de Larrea CF; Navarro A; Díaz T; Fuster D; Tovar N; Rosiñol L; Monzó M; Bladé J
Leuk Res; 2011 Sep; 35(9):1178-83. PubMed ID: 21435719
[TBL] [Abstract][Full Text] [Related]
4. Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide.
Almasi M; Sevcikova S; Slaby O; Kaisarova P; Maisnar V; Penka M; Pika T; Pour L; Radocha J; Scudla V; Svachova H; Hajek R
Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):414-20. PubMed ID: 21859556
[TBL] [Abstract][Full Text] [Related]
5. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature.
Badros A; Goloubeva O; Dalal JS; Can I; Thompson J; Rapoport AP; Heyman M; Akpek G; Fenton RG
Cancer; 2007 Sep; 110(5):1042-9. PubMed ID: 17654660
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan.
Dumontet C; Landi S; Reiman T; Perry T; Plesa A; Bellini I; Barale R; Pilarski LM; Troncy J; Tavtigian S; Gemignani F
Bone Marrow Transplant; 2010 Aug; 45(8):1316-24. PubMed ID: 19966851
[TBL] [Abstract][Full Text] [Related]
7. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.
Johnson DC; Corthals SL; Walker BA; Ross FM; Gregory WM; Dickens NJ; Lokhorst HM; Goldschmidt H; Davies FE; Durie BG; Van Ness B; Child JA; Sonneveld P; Morgan GJ
J Clin Oncol; 2011 Mar; 29(7):797-804. PubMed ID: 21245421
[TBL] [Abstract][Full Text] [Related]
8. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.
Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH
Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621
[TBL] [Abstract][Full Text] [Related]
9. Expression of genes of potential importance in the response to chemotherapy and DNA repair in patients with ovarian cancer.
Codegoni AM; Broggini M; Pitelli MR; Pantarotto M; Torri V; Mangioni C; D'Incalci M
Gynecol Oncol; 1997 Apr; 65(1):130-7. PubMed ID: 9103402
[TBL] [Abstract][Full Text] [Related]
10. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comparison between previously treated and untreated patients.
Corso A; Mangiacavalli S; Varettoni M; Pascutto C; Zappasodi P; Lazzarino M
Leuk Res; 2010 Apr; 34(4):471-4. PubMed ID: 19674790
[TBL] [Abstract][Full Text] [Related]
11. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma.
Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P
Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586
[TBL] [Abstract][Full Text] [Related]
12. Venous thromboembolism in multiple myeloma: current perspectives in pathogenesis.
Uaprasert N; Voorhees PM; Mackman N; Key NS
Eur J Cancer; 2010 Jul; 46(10):1790-9. PubMed ID: 20385482
[TBL] [Abstract][Full Text] [Related]
13. Impact of Genetic Polymorphisms in NF-ĸB2 and TRAF3 Genes on Response to Bortezomib-Based Therapy in Multiple Myeloma Patients.
Sood N; Hamide A; Dubashi B; Nisha Y; Mathaiyan J; Munirajan AK; Ganesn P; Kayal S
Asian Pac J Cancer Prev; 2024 Mar; 25(3):829-837. PubMed ID: 38546066
[TBL] [Abstract][Full Text] [Related]
14. Genetic variations in multiple myeloma I: effect on risk of multiple myeloma.
Vangsted A; Klausen TW; Vogel U
Eur J Haematol; 2012 Jan; 88(1):8-30. PubMed ID: 21883480
[TBL] [Abstract][Full Text] [Related]
15. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation.
Anglicheau D; Thervet E; Etienne I; Hurault De Ligny B; Le Meur Y; Touchard G; Büchler M; Laurent-Puig P; Tregouet D; Beaune P; Daly A; Legendre C; Marquet P
Clin Pharmacol Ther; 2004 May; 75(5):422-33. PubMed ID: 15116055
[TBL] [Abstract][Full Text] [Related]
16. Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients?
Palumbo A; Mateos MV; Bringhen S; San Miguel JF
Blood Rev; 2011 Jul; 25(4):181-91. PubMed ID: 21497966
[TBL] [Abstract][Full Text] [Related]
17. Prospective evaluation of coagulopathy in multiple myeloma patients before, during and after various chemotherapeutic regimens.
van Marion AM; Auwerda JJ; Lisman T; Sonneveld P; de Maat MP; Lokhorst HM; Leebeek FW
Leuk Res; 2008 Jul; 32(7):1078-84. PubMed ID: 18241919
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia.
Krajinovic M; Labuda D; Mathonnet G; Labuda M; Moghrabi A; Champagne J; Sinnett D
Clin Cancer Res; 2002 Mar; 8(3):802-10. PubMed ID: 11895912
[TBL] [Abstract][Full Text] [Related]
19. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
[TBL] [Abstract][Full Text] [Related]
20. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma.
Ladetto M; Pagliano G; Ferrero S; Cavallo F; Drandi D; Santo L; Crippa C; De Rosa L; Pregno P; Grasso M; Liberati AM; Caravita T; Pisani F; Guglielmelli T; Callea V; Musto P; Cangialosi C; Passera R; Boccadoro M; Palumbo A
J Clin Oncol; 2010 Apr; 28(12):2077-84. PubMed ID: 20308672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
